Funder: California Institute for Regenerative Medicine
Due Dates (Anticipated): October 2027 (PDEV application deadline)
Funding Amounts: PDEV: up to $13 million total costs over five years
Summary: Supports preclinical development of stem cell-based and genetic therapies toward clinical readiness, with priorities including transformative patient benefit and improved access.
Key Information: PDEV applicants must qualify as California Organizations and pursue FDA clearance of a single IND application.
Description
The California Institute for Regenerative Medicine (CIRM) supports complementary preclinical funding opportunities for stem cell-based and genetic therapies. Its Preclinical Development (PDEV) program funds work from candidate optimization through IND-enabling studies and clinical trial startup. All PDEV awards must aim for FDA Investigational New Drug (IND) clearance, advancing therapies for diseases affecting Californians toward first-in-human trials.
PDEV combines funding with CIRM staff and external expert support, emphasizing data and knowledge sharing, transformative clinical outcomes, and planning to overcome patient access barriers. The complementary Rare Disease Acceleration Through Platform Innovation and Delivery (RAPID) program advances the development and delivery of platform-based genetic therapies for Americans with rare diseases.
